The Challenge of Infection Outcomes in Clinical Trials

Affiliations

Comment

Robin Avery. Transplantation. 2021.

. 2021 Dec 1;105(12):2522-2523.

doi: 10.1097/TP.0000000000003724.

¹ Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD.

No abstract available

Comment on

Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review.
Chan S, Au E, Johnson DW, Hawley CM, Tong A, Pascoe EM, Craig JC, Sautenet B, Blumberg EA, Brennan D, Campbell SB, Cao C, Francis RS, Huuskes B, Isbel NM, Knoll G, Kotton CN, Mamode N, Muller E, An Ha Phan H, Tedesco-Silva H, White DM, Wolley MJ, Viecelli AK. Chan S, et al. Transplantation. 2021 Dec 1;105(12):2632-2638. doi: 10.1097/TP.0000000000003723. Transplantation. 2021. PMID: 33653998

1. de Paula MI, Bae S, Shaffer AA, et al. The influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis. Transplantation. 2020;104:2139–2147.
1. Karadkhele G, Hogan J, Magua W, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant. 2021;21:208–221.
1. Avery RK, Motter JD, Jackson KR, et al. Quantifying infection risks in incompatible living donor kidney transplant recipients. Am J Transplant. 2020;21:1564–1575.
1. Chan S, Au E, Johnson DW, et al. Range and consistency of infection outcomes reported in trials conducted in kidney transplant recipients: a systematic review. Transplantation. 2021;105:2632–2638.
1. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–274.